Emergent BioSolutions (EBS) investor relations material

Executive summary

• Q3 revenue was $110.0M, down 52% YoY and within guidance; 9M revenue was $500.4M, down 16%.

• 9M Adjusted EBITDA was $127.5M, or 25% of revenue; operating cash flow was $122.4M and quarter-end liquidity was $226M.

• Priorities included cost discipline, debt reduction, differentiated growth programs, R&D investment and international expansion.

Financial highlights

• Q3 net loss was $32.7M versus net income of $51.2M; adjusted net loss was $18.7M.

• Q3 Adjusted EBITDA was $(4.6)M, or (4)% margin, versus $92.6M and 40%; adjusted gross margin was 28% versus 62%.

• Q3 gross margin was 14% of product and services sales versus 54%; Q3 SG&A and R&D were $56M, including $8M of restructuring costs.

• 9M Adjusted EBITDA was $127.5M versus $204.8M; adjusted gross margin was 49% versus 57%.

• 9M net loss was $206.1M versus net income of $107.2M; adjusted net income was $24.1M versus $120.5M.

Outlook and guidance

• FY2026 revenue guidance was reduced to $600M–$645M from $645M–$675M, reflecting expected U.S. and international MCM sales timing.

• Adjusted EBITDA guidance was lowered to $110M–$140M from $130M–$150M; adjusted net income guidance is a loss of $10M to income of $20M.

• Adjusted gross margin guidance rose to 45%–47% from 42%–44%, reflecting manufacturing improvements, product mix and stabilized U.S. public-interest NARCAN pricing.

• Commercial revenue is expected to decline 20%–25% YoY; guidance assumes ~$38M interest expense and ~$16M capex.

• MCM revenue is expected to decline YoY; some U.S. and international orders may shift beyond Q4 into early 2027.